AR124123A1 - Anticuerpos anti-cd25 - Google Patents
Anticuerpos anti-cd25Info
- Publication number
- AR124123A1 AR124123A1 ARP210103224A ARP210103224A AR124123A1 AR 124123 A1 AR124123 A1 AR 124123A1 AR P210103224 A ARP210103224 A AR P210103224A AR P210103224 A ARP210103224 A AR P210103224A AR 124123 A1 AR124123 A1 AR 124123A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- cdr1
- cdr2
- cdr3
- cdrs
- Prior art date
Links
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a anticuerpos anti-CD25 humano novedosos y a su utilización para el tratamiento de un cáncer y enfermedades infecciosas. Reivindicación 1: Un anticuerpo anti-CD25 humano aislado o fragmento de unión a antígeno del mismo, en donde la región variable de la cadena pesada (VH) comprende las tres siguientes regiones determinantes de complementariedad (CDR): CDR1: NHAMA (SEQ ID Nº 1); CDR2: VISYDGX¹NX²YYX³DSVKG (SEQ ID Nº 2), en donde X¹ es S o D, X² es K o T, X³ es A o R; y CDR3: GX⁴NSGYD (SEQ ID Nº 3), en donde X⁴ es W o L; o cualquier CDR que tiene una secuencia de aminoácidos que comparte al menos aproximadamente 95% de identidad con SEQ ID Nº 1 - 3; y en donde la región variable de la cadena liviana (VL) comprende las tres CDR siguientes: CDR1: RASQX⁵X⁶X⁷X⁸X⁹LN (SEQ ID Nº 4), en donde X⁵ es S o N, X⁶ es V o I, X⁷ es N o S, X⁸ es S o K, X⁹ es F o Y; y CDR2: GTX¹⁰SLQS (SEQ ID Nº 5), en donde X¹⁰ es S o N; y CDR3: QQYX¹¹SWPWT (SEQ ID Nº 6), en donde X¹¹ es T o N; o cualquier CDR que tiene una secuencia de aminoácidos que comparte al menos aproximadamente 95% de identidad con SEQ ID Nº 4 - 6.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306424 | 2020-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124123A1 true AR124123A1 (es) | 2023-02-15 |
Family
ID=73698744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103224A AR124123A1 (es) | 2020-11-20 | 2021-11-19 | Anticuerpos anti-cd25 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240002522A1 (es) |
| EP (1) | EP4247497A1 (es) |
| JP (1) | JP2023550446A (es) |
| KR (1) | KR20230118108A (es) |
| CN (1) | CN116917318A (es) |
| AR (1) | AR124123A1 (es) |
| AU (1) | AU2021380966A1 (es) |
| CA (1) | CA3199006A1 (es) |
| WO (1) | WO2022106665A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023222886A1 (en) | 2022-05-20 | 2023-11-23 | Depth Charge Ltd | Antibody-cytokine fusion proteins |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US96973A (en) | 1869-11-16 | saxton | ||
| US61816A (en) | 1867-02-05 | bunbab and a | ||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| ATE135370T1 (de) | 1988-12-22 | 1996-03-15 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991010741A1 (en) | 1990-01-12 | 1991-07-25 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0617706T3 (da) | 1991-11-25 | 2001-11-12 | Enzon Inc | Multivalente antigenbindende proteiner |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| EP2275541B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| DK1522590T3 (da) | 2000-06-28 | 2009-12-21 | Glycofi Inc | Fremgangsmåde til fremstilling af modificerede glykoproteiner |
| EP1916303B1 (en) | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| US20030157108A1 (en) | 2001-10-25 | 2003-08-21 | Genentech, Inc. | Glycoprotein compositions |
| CA2688834C (en) | 2007-06-01 | 2020-01-07 | Ronald Buelow | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
| US11879014B2 (en) * | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
| US20200283535A1 (en) * | 2017-07-06 | 2020-09-10 | Tusk Therapeutics Ltd. | Compounds and methods for tumour-specific cell depletion |
| EP3765502B1 (en) * | 2018-03-13 | 2024-08-07 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| WO2020234399A1 (en) * | 2019-05-20 | 2020-11-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Novel anti-cd25 antibodies |
-
2021
- 2021-11-19 CA CA3199006A patent/CA3199006A1/en active Pending
- 2021-11-19 JP JP2023530329A patent/JP2023550446A/ja active Pending
- 2021-11-19 US US18/253,493 patent/US20240002522A1/en active Pending
- 2021-11-19 CN CN202180090876.8A patent/CN116917318A/zh active Pending
- 2021-11-19 KR KR1020237019908A patent/KR20230118108A/ko unknown
- 2021-11-19 EP EP21807150.4A patent/EP4247497A1/en active Pending
- 2021-11-19 AU AU2021380966A patent/AU2021380966A1/en active Pending
- 2021-11-19 WO PCT/EP2021/082383 patent/WO2022106665A1/en active Application Filing
- 2021-11-19 AR ARP210103224A patent/AR124123A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116917318A (zh) | 2023-10-20 |
| JP2023550446A (ja) | 2023-12-01 |
| CA3199006A1 (en) | 2022-05-27 |
| KR20230118108A (ko) | 2023-08-10 |
| US20240002522A1 (en) | 2024-01-04 |
| AU2021380966A1 (en) | 2023-06-22 |
| EP4247497A1 (en) | 2023-09-27 |
| WO2022106665A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017052784A5 (es) | ||
| IL266756A (en) | Human monoclonal antibodies that bind to MASP 2 and suppress MASP-dependent complement activation, methods for their production and uses | |
| JP2019201643A5 (es) | ||
| JP2019122405A5 (es) | ||
| AR108067A1 (es) | Moléculas de unión y métodos de uso de los mismos | |
| PE20030846A1 (es) | Anticuerpos para cd40 | |
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
| JP2015525795A5 (es) | ||
| RU2020111211A (ru) | Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента | |
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 | |
| JP2020514277A5 (es) | ||
| RU2015118180A (ru) | Антитела к бета-амилоиду | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| IL250289B2 (en) | Antibodies against angiopoietin-like 4 and methods of use | |
| RU2018100824A (ru) | Антитела, которые связываются с сортилином и подавляют связывание програнулина | |
| FI3515947T3 (fi) | Uudet tekijän XI vasta-aineet ja niiden käyttökohteet | |
| CO6180454A2 (es) | Anticuerpos de la egfl7 y metodos de uso | |
| AR124123A1 (es) | Anticuerpos anti-cd25 | |
| AR123306A1 (es) | Anticuerpos fgfr3 y métodos de uso | |
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| RU2018129180A (ru) | Тромбиновое антитело, антиген-связывающий фрагмент и их фармацевтическое применение | |
| JPWO2020014460A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |